
Hi, Ong,
There are a number of reasons:
1. If you saw my earlier posting on 12 Sep, I mentioned about the formation breakout and indicated an upward potential of $2.77. That has been realised.
2. RSI of the the counter has gone into overbought 2 days' ago. Candle stick also indicated a possible reversal on 27 Sep.
3. The run up so far has been due to its resolution of its problem of Pantai in Malaysia. With the latest announcement of special dividend and rights issue, there is no visible price catalyst going ahead. With its PE ratio runing at above 30, we should exercise caution.
Hence, if you already have made profit, I recommend taking profit.
This is just my analysis as requested. For reference only.
Allan hi,
need your insight. Go as high as 2.88 and now is 2.83. What is your rational for taking profit? Thanks.
Time to take profit now.
Parkway Holdings said it is distributing a pretax special interim cash dividend of $0.1125 or net $0.09 per ordinary share, and a 1-for-20 rights issue of up to 36.50m rights shares priced at $1.80 each.
The special dividend is to reward shareholders and provide them with an option to re-invest by subscribing to the rights shares, while allowing Parkway to pass on its tax credits available under Section 44A of the Income tax Act of Singapore to shareholders.
"The rights issue has been proposed to strengthen the capital base of Parkway," the group said in a statement.
It was higher after announcing to media that it expects its operations in India to be profitable next year, dealers said.
DBSV analyst James Tan said media reports about the outlook for its India operations and Parkway's recent joint venture with Malaysia's Khazanah Nasional Bhd fuelled positive sentiment for the firm.
"The JV is positive as Parkway can leverage on Khazanah to help them explore and further expand into Malaysia's growing healthcare market," Tan said. "Going forward, things seems to be going in the right direction for Parkway," he added.
Tan, however, maintains a "hold" rating for Parkway with a target price of $2.44, as he sees limited upside for the stock for now.
Parkway has just cleared its resistance at $2.57. The next resistance is at $2.63. The counter moved out of its wedge formation recently. Technically, it has a potential to reach $2.77.
Just for sharing and reference. Would welcome other perspectives/comments both convergent and divergent from Forum members.
It expects its clinics in India to begin generating profits next year, while its other overseas medical centres in Vietnam and China continue to incur losses.
Newton Investment Management bought 1.257 million shares through open market and raises its stake from 5.95% to 6.13%. Good sign.
TA charts look pretty good. However, this counter's volume is inconsistent.
Technically, Parkway is looking quite good now. It has broken out of a triangular formation. Resistance is now at $2.57 and after that $2.63. If you are thinking of entering at this point, stop loss should be at $2.35.
Just for sharing and reference. Not an inducement to trade.
Khazanah said it had reached agreement with Parkway, whereby Parkway's 31% stake in Pantai would be sold to a Khazanah-controlled joint venture. Parkway hold 49% of the new venture.
Parkway finalised a loan of $500m in a move that some analysts see as preparation for further regional expansion. It's already expanding into Vietnam, Shanghai and India. It has a stake in Malaysia's largest private health-care provider Pantai.
In India, Parkway has a JV called Apollo Gleneagles Hospital in Kolkata with the Apollo Hospitals Group. It recently set up an aesthetics clinic in Vietnam and a new medical centre in China.
Citigroup Research just recommended a BUY on this counter.
Not vested.